{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:16:42Z","timestamp":1788139002575,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["5I01RX000441-04"],"award-info":[{"award-number":["5I01RX000441-04"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["5R01DK100281-03"],"award-info":[{"award-number":["5R01DK100281-03"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS086074"],"award-info":[{"award-number":["R01NS086074"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS092093"],"award-info":[{"award-number":["R01NS092093"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS108686"],"award-info":[{"award-number":["R01NS108686"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG062135"],"award-info":[{"award-number":["R01AG062135"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD), classically defined as a progressive motor disorder accompanied with dopaminergic neuron loss and presence of Lewy bodies, is the second most common neurodegenerative disease. PD also has various non-classical symptoms, including cognitive impairments. In addition, inflammation and astrogliosis are recognized as an integral part of PD pathology. The hippocampus (Hipp) is a brain region involved in cognition and memory, and the neuropeptide orexin has been shown to enhance learning and memory. Previous studies show impairments in Hipp-dependent memory in a transgenic mouse model of Parkinson\u2019s disease (A53T mice), and we hypothesized that increasing orexin tone will reverse this. To test this, we subjected 3, 5, and 7-month old A53T mice to a Barnes maze and a contextual object recognition test to determine Hipp dependent memory. Inflammation and astrogliosis markers in the Hipp were assessed by immuno-fluorescence densitometry. The data show that early cognitive impairment is coupled with an increase in expression of inflammatory and astrogliosis markers. Next, in two separate experiments, mice were given intra-hippocampal injections of orexin or chemogenetic viral injections of an orexin neuron specific Designer Receptor Exclusively Activated by Designer Drug (DREADD). For the pharmacological approach mice were intracranially treated with orexin A, whereas the chemogenetic approach utilized clozapine N-oxide (CNO). Both pharmacological orexin A intervention as well as chemogenetic activation of orexin neurons ameliorated Hipp-dependent early memory impairment observed in A53T mice. This study implicates orexin in PD-associated cognitive impairment and suggests that exogenous orexin treatment and\/or manipulation of endogenous orexin levels may be a potential strategy for addressing early cognitive loss in PD.<\/jats:p>","DOI":"10.1186\/s13041-019-0514-8","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T23:03:14Z","timestamp":1572476594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pharmacological and chemogenetic orexin\/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-3712","authenticated-orcid":false,"given":"Milos","family":"Stanojlovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Pallais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Kotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"514_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.","journal-title":"Nat Rev Dis Primers"},{"key":"514_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brainresbull.2017.03.009","volume":"133","author":"A Anandhan","year":"2017","unstructured":"Anandhan A, Jacome MS, Lei S, Hernandez-Franco P, Pappa A, Panayiotidis MI, et al. Metabolic dysfunction in Parkinson\u2019s disease: bioenergetics, redox homeostasis and central carbon metabolism. Brain Res Bull. 2017;133:12\u201330.","journal-title":"Brain Res Bull"},{"key":"514_CR3","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/S1353-8020(11)70024-4","volume":"18","author":"LCS Tan","year":"2012","unstructured":"Tan LCS. Mood disorders in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18:S74\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1212\/CPJ.0000000000000285","volume":"6","author":"AA Davis","year":"2016","unstructured":"Davis AA, Racette B. Parkinson disease and cognitive impairment. Neurol Clin Pract. 2016;6:452\u20138.","journal-title":"Neurol Clin Pract"},{"key":"514_CR5","first-page":"441","volume":"102","author":"JG Goldman","year":"2011","unstructured":"Goldman JG, Litvan I. Mild cognitive impairment in Parkinson\u2019s disease. Minerva Med. 2011;102:441\u201359.","journal-title":"Minerva Med"},{"key":"514_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/B978-0-444-59489-1.00005-7","volume":"198","author":"EM Girault","year":"2012","unstructured":"Girault EM, Yi C-X, Fliers E, Kalsbeek A. Orexins, feeding, and energy balance. Prog Brain Res. 2012;198:47\u201364.","journal-title":"Prog Brain Res"},{"key":"514_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/pr.109.001321","volume":"61","author":"N Tsujino","year":"2009","unstructured":"Tsujino N, Sakurai T. Orexin\/Hypocretin: a neuropeptide at the Interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61:162\u201376.","journal-title":"Pharmacol Rev"},{"key":"514_CR8","doi-asserted-by":"crossref","unstructured":"Inutsuka A, Yamanaka A. The physiological role of orexin\/hypocretin neurons in the regulation of sleep\/wakefulness and neuroendocrine functions. Front Endocrinol. 2013;4 [cited 2017 Mar 18]. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2013.00018\/abstract .","DOI":"10.3389\/fendo.2013.00018"},{"key":"514_CR9","doi-asserted-by":"crossref","unstructured":"De Lecea L, Huerta R. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5 [cited 2018 Aug 30]. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2014.00016\/full .","DOI":"10.3389\/fphar.2014.00016"},{"key":"514_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.physbeh.2006.05.031","volume":"88","author":"CM Kotz","year":"2006","unstructured":"Kotz CM. Integration of feeding and spontaneous physical activity: role for orexin. Physiol Behav. 2006;88:294\u2013301.","journal-title":"Physiol Behav"},{"key":"514_CR11","doi-asserted-by":"crossref","unstructured":"Perez-Leighton C, Little MR, Grace M, Billington C, Kotz CM. Orexin signaling in rostral lateral hypothalamus and nucleus accumbens shell in the control of spontaneous physical activity in high- and low-activity rats. Am J Physiol Regul Integr Comp Physiol. 2017;312:R338\u201346.","DOI":"10.1152\/ajpregu.00339.2016"},{"key":"514_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neuron.2005.03.010","volume":"46","author":"T Sakurai","year":"2005","unstructured":"Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, et al. Input of orexin\/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron. 2005;46:297\u2013308.","journal-title":"Neuron."},{"key":"514_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/cne.20859","volume":"494","author":"K Yoshida","year":"2006","unstructured":"Yoshida K, McCormack S, Espa\u00f1a RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol. 2006;494:845\u201361.","journal-title":"J Comp Neurol"},{"key":"514_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-444-59489-1.00009-4","volume":"198","author":"PL Johnson","year":"2012","unstructured":"Johnson PL, Molosh A, Fitz SD, Truitt WA, Shekhar A. Orexin, stress, and anxiety\/panic states. Prog Brain Res. 2012;198:133\u201361.","journal-title":"Prog Brain Res"},{"key":"514_CR15","doi-asserted-by":"crossref","unstructured":"Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci. 2014;8 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3934415\/ .","DOI":"10.3389\/fnins.2014.00036"},{"key":"514_CR16","doi-asserted-by":"publisher","first-page":"E1648","DOI":"10.1073\/pnas.1315542111","volume":"111","author":"JW Muschamp","year":"2014","unstructured":"Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. PNAS. 2014;111:E1648\u201355.","journal-title":"PNAS."},{"key":"514_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nlm.2017.10.014","volume":"146","author":"V Mavanji","year":"2017","unstructured":"Mavanji V, Butterick TA, Duffy CM, Nixon JP, Billington CJ, Kotz CM. Orexin\/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiol Learn Mem. 2017;146:21\u201330.","journal-title":"Neurobiol Learn Mem"},{"key":"514_CR18","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1038\/npp.2014.146","volume":"39","author":"\u00c1 Flores","year":"2014","unstructured":"Flores \u00c1, Valls-Comamala V, Costa G, Saravia R, Maldonado R, Berrendero F. The Hypocretin\/Orexin system mediates the extinction of fear memories. Neuropsychopharmacology. 2014;39:2732\u201341.","journal-title":"Neuropsychopharmacology."},{"key":"514_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/7854_2016_56","volume":"33","author":"MH James","year":"2017","unstructured":"James MH, Campbell EJ, Dayas CV. Role of the Orexin\/Hypocretin system in stress-related psychiatric disorders. Curr Top Behav Neurosci. 2017;33:197\u2013219.","journal-title":"Curr Top Behav Neurosci"},{"key":"514_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.biopha.2017.03.053","volume":"90","author":"BM Razavi","year":"2017","unstructured":"Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation. Biomed Pharmacother. 2017;90:187\u201393.","journal-title":"Biomed Pharmacother"},{"key":"514_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1365-2869.2012.01027.x","volume":"21","author":"M Wienecke","year":"2012","unstructured":"Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, et al. Progressive dopamine and hypocretin deficiencies in Parkinson\u2019s disease: is there an impact on sleep and wakefulness? J Sleep Res. 2012;21:710\u20137.","journal-title":"J Sleep Res"},{"key":"514_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","volume":"61","author":"X Drouot","year":"2003","unstructured":"Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Cr\u00e9ange A, Remy P, et al. Low levels of ventricular CSF orexin\/hypocretin in advanced PD. Neurology. 2003;61:540\u20133.","journal-title":"Neurology."},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/brain\/awm090","volume":"130","author":"R Fronczek","year":"2007","unstructured":"Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson\u2019s disease. Brain. 2007;130:1577\u201385.","journal-title":"Brain."},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/awm097","volume":"130","author":"TC Thannickal","year":"2007","unstructured":"Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson\u2019s disease. Brain. 2007;130:1586\u201395.","journal-title":"Brain."},{"key":"514_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/NSS.S41245","volume":"5","author":"A Bridoux","year":"2013","unstructured":"Bridoux A, Moutereau S, Covali-Noroc A, Margarit L, Palfi S, Nguyen J-P, et al. Ventricular orexin-a (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson\u2019s disease. Nat Sci Sleep. 2013;5:87\u201391.","journal-title":"Nat Sci Sleep"},{"key":"514_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm220","volume":"131","author":"CR Baumann","year":"2008","unstructured":"Baumann CR, Scammell TE, Bassetti CL. Parkinson\u2019s disease, sleepiness and hypocretin\/orexin. Brain. 2008;131:e91.","journal-title":"Brain."},{"key":"514_CR27","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1073\/pnas.0811126106","volume":"106","author":"T Matsuki","year":"2009","unstructured":"Matsuki T, Nomiyama M, Takahira H, Hirashima N, Kunita S, Takahashi S, et al. Selective loss of GABA(B) receptors in orexin-producing neurons results in disrupted sleep\/wakefulness architecture. Proc Natl Acad Sci U S A. 2009;106:4459\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"514_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ijo.2017.276","volume":"42","author":"AN Zink","year":"2018","unstructured":"Zink AN, Bunney PE, Holm AA, Billington CJ, Kotz CM. Neuromodulation of orexin neurons reduces diet-induced adiposity. Int J Obes (Lond). 2018;42:737\u201345.","journal-title":"Int J Obes (Lond)"},{"key":"514_CR29","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1073\/pnas.132197599","volume":"99","author":"MK Lee","year":"2002","unstructured":"Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human \u03b1-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 \u2192 Thr mutation causes neurodegenerative disease with \u03b1-synuclein aggregation in transgenic mice. PNAS. 2002;99:8968\u201373.","journal-title":"PNAS."},{"key":"514_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.biopsych.2015.10.004","volume":"80","author":"NC Victoria","year":"2016","unstructured":"Victoria NC, de Velasco EMF, Ostrovskaya O, Metzger S, Xia Z, Kotecki L, et al. G protein-gated K+ channel ablation in forebrain pyramidal neurons selectively impairs fear learning. Biol Psychiatry. 2016;80:796\u2013806.","journal-title":"Biol Psychiatry"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fnbeh.2015.00182","volume":"9","author":"S Kanatsou","year":"2015","unstructured":"Kanatsou S, Kuil LE, Arp M, Oitzl MS, Harris AP, Seckl JR, et al. Overexpression of mineralocorticoid receptors does not affect memory and anxiety-like behavior in female mice. Front Behav Neurosci. 2015;9:182.","journal-title":"Front Behav Neurosci"},{"key":"514_CR32","volume-title":"The mouse brain in stereotaxic coordinates","author":"K Franklin","year":"2008","unstructured":"Franklin K. The mouse brain in stereotaxic coordinates. Amsterdam: Acad. Press; 2008."},{"key":"514_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aan2475","volume":"357","author":"JL Gomez","year":"2017","unstructured":"Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 2017;357:503\u20137.","journal-title":"Science."},{"key":"514_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384\u20136.","journal-title":"Neurology."},{"key":"514_CR35","first-page":"292","volume":"46","author":"L Hirsch","year":"2016","unstructured":"Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson\u2019s disease: a systematic review and meta-analysis. NED. 2016;46:292\u2013300.","journal-title":"NED."},{"key":"514_CR36","doi-asserted-by":"crossref","unstructured":"Kim I, Shin N-Y, Bak Y, Hyu Lee P, Lee S-K, Mee Lim S. Early-onset mild cognitive impairment in Parkinson\u2019s disease: Altered corticopetal cholinergic network. Sci Rep. 2017;7 [cited 2019 Apr 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5443757\/ .","DOI":"10.1038\/s41598-017-02420-w"},{"key":"514_CR37","first-page":"331","volume":"4","author":"RA Lawson","year":"2014","unstructured":"Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Quality of life and mild cognitive impairment in early Parkinson\u2019s disease: does subtype matter? J Park Dis. 2014;4:331\u20136.","journal-title":"J Park Dis"},{"key":"514_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","volume":"20","author":"GS Watson","year":"2010","unstructured":"Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson disease. Brain Pathol. 2010;20:640\u20135.","journal-title":"Brain Pathol"},{"key":"514_CR39","doi-asserted-by":"crossref","unstructured":"Weil RS, Costantini AA, Schrag AE. Mild Cognitive Impairment in Parkinson\u2019s Disease\u2014What Is It? Curr Neurol Neurosci Rep. 2018;18 [cited 2019 Apr 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5845587\/ .","DOI":"10.1007\/s11910-018-0823-9"},{"key":"514_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jnc.12481","volume":"128","author":"KF Farrell","year":"2014","unstructured":"Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TNM, Peet E, et al. Non-motor parkinsonian pathology in aging A53T \u03b1-Synuclein mice is associated with progressive synucleinopathy and altered enzymatic function. J Neurochem. 2014;128:536\u201346.","journal-title":"J Neurochem"},{"key":"514_CR41","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jnr.22331","volume":"88","author":"DR Graham","year":"2010","unstructured":"Graham DR, Sidhu A. Mice expressing the A53T mutant form of human alpha-Synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res. 2010;88:1777\u201383.","journal-title":"J Neurosci Res"},{"key":"514_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.nbd.2005.08.005","volume":"21","author":"EL Unger","year":"2006","unstructured":"Unger EL, Eve DJ, Perez XA, Reichenbach DK, Xu Y, Lee MK, et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Neurobiol Dis. 2006;21:431\u201343.","journal-title":"Neurobiol Dis"},{"key":"514_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070274","volume":"8","author":"KL Paumier","year":"2013","unstructured":"Paumier KL, Rizzo SJS, Berger Z, Chen Y, Gonzales C, Kaftan E, et al. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson\u2019s disease. PLoS One. 2013;8:e70274.","journal-title":"PLoS One"},{"key":"514_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.4196\/kjpp.2017.21.6.625","volume":"21","author":"S Lee","year":"2017","unstructured":"Lee S, Oh ST, Jeong HJ, Pak SC, Park H-J, Kim J, et al. MPTP-induced vulnerability of dopamine neurons in A53T \u03b1-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation. Korean J Physiol Pharmacol. 2017;21:625\u201332.","journal-title":"Korean J Physiol Pharmacol"},{"key":"514_CR45","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1523\/JNEUROSCI.0089-14.2015","volume":"35","author":"Z Xie","year":"2015","unstructured":"Xie Z, Turkson S, Zhuang X. A53T human \u03b1-Synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J Neurosci. 2015;35:890\u2013905.","journal-title":"J Neurosci"},{"key":"514_CR46","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/S1353-8020(11)70064-5","volume":"18","author":"S Phani","year":"2012","unstructured":"Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18:S207\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"514_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tins.2017.04.001","volume":"40","author":"HDE Booth","year":"2017","unstructured":"Booth HDE, Hirst WD, Wade-Martins R. The role of astrocyte dysfunction in Parkinson\u2019s disease pathogenesis. Trends Neurosci. 2017;40:358\u201370.","journal-title":"Trends Neurosci"},{"key":"514_CR48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00401-011-0833-z","volume":"121","author":"L Fellner","year":"2011","unstructured":"Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of \u03b1-synucleinopathies: emerging concepts. Acta Neuropathol. 2011;121:675\u201393.","journal-title":"Acta Neuropathol"},{"key":"514_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-6606-3-12","volume":"3","author":"X-L Gu","year":"2010","unstructured":"Gu X-L, Long C-X, Sun L, Xie C, Lin X, Cai H. Astrocytic expression of Parkinson\u2019s disease-related A53T \u03b1-synuclein causes neurodegeneration in mice. Mol Brain. 2010;3:12.","journal-title":"Mol Brain"},{"key":"514_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12974-018-1302-6","volume":"15","author":"R-H Du","year":"2018","unstructured":"Du R-H, Zhou Y, Xia M-L, Lu M, Ding J-H, Hu G. \u03b1-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering \u03b2-arrestin2-TAB1 interaction in astrocytes. J Neuroinflammation. 2018;15:258.","journal-title":"J Neuroinflammation"},{"key":"514_CR51","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1523\/JNEUROSCI.4977-09.2010","volume":"30","author":"E Tsika","year":"2010","unstructured":"Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, et al. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci. 2010;30:3409\u201318.","journal-title":"J Neurosci"},{"key":"514_CR52","doi-asserted-by":"publisher","unstructured":"Singh B, Covelo A, Martell-Mart\u00ednez H, Nanclares C, Sherman MA, Okematti E, et al. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathol. 2019 [cited 2019 Jul 1]; Available from. https:\/\/doi.org\/10.1007\/s00401-019-02032-w .","DOI":"10.1007\/s00401-019-02032-w"},{"key":"514_CR53","doi-asserted-by":"publisher","first-page":"9754","DOI":"10.1523\/JNEUROSCI.0344-18.2018","volume":"38","author":"PJ Teravskis","year":"2018","unstructured":"Teravskis PJ, Covelo A, Miller EC, Singh B, Martell-Mart\u00ednez HA, Benneyworth MA, et al. A53T mutant alpha-Synuclein induces tau-dependent postsynaptic impairment independently of neurodegenerative changes. J Neurosci. 2018;38:9754\u201367.","journal-title":"J Neurosci"},{"key":"514_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbi.2012.09.003","volume":"27","author":"RA Kohman","year":"2013","unstructured":"Kohman RA, Rhodes JS. Neurogenesis, inflammation and behavior. Brain Behav Immun. 2013;27:22\u201332.","journal-title":"Brain Behav Immun"},{"key":"514_CR55","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bbadis.2015.11.014","volume":"1862","author":"M Pekny","year":"2016","unstructured":"Pekny M, Pekna M. Reactive gliosis in the pathogenesis of CNS diseases. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2016;1862:483\u201391.","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"514_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","volume":"119","author":"MV Sofroniew","year":"2010","unstructured":"Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7\u201335.","journal-title":"Acta Neuropathol"},{"key":"514_CR57","doi-asserted-by":"crossref","unstructured":"Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, et al. Orexin System: The Key for a Healthy Life. Front Physiol. 2017;8 [cited 2019 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5450021\/ .","DOI":"10.3389\/fphys.2017.00357"},{"key":"514_CR58","doi-asserted-by":"publisher","first-page":"20260","DOI":"10.1073\/pnas.1320325110","volume":"110","author":"RM Sears","year":"2013","unstructured":"Sears RM, Fink AE, Wigestrand MB, Farb CR, de Lecea L, LeDoux JE. Orexin\/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus. PNAS. 2013;110:20260\u20135.","journal-title":"PNAS."},{"key":"514_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1101\/lm.033688.113","volume":"21","author":"B Ferry","year":"2014","unstructured":"Ferry B, Duchamp-Viret P. The orexin component of fasting triggers memory processes underlying conditioned food selection in the rat. Learn Mem. 2014;21:185\u20139.","journal-title":"Learn Mem"},{"key":"514_CR60","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1523\/JNEUROSCI.3200-12.2013","volume":"33","author":"L Yang","year":"2013","unstructured":"Yang L, Zou B, Xiong X, Pascual C, Xie J, Malik A, et al. Hypocretin\/Orexin neurons contribute to Hippocampus-dependent social memory and synaptic plasticity in mice. J Neurosci. 2013;33:5275\u201384.","journal-title":"J Neurosci"},{"key":"514_CR61","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5483\/BMBRep.2017.50.5.038","volume":"50","author":"JR Bae","year":"2017","unstructured":"Bae JR, Kim SH. Synapses in neurodegenerative diseases. BMB Rep. 2017;50:237\u201346.","journal-title":"BMB Rep"},{"key":"514_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/01.jnen.0000228202.35163.c4","volume":"65","author":"TM Wishart","year":"2006","unstructured":"Wishart TM, Parson SH, Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol. 2006;65:733\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"514_CR63","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/npjparkd.2016.18","volume":"2","author":"R Biundo","year":"2016","unstructured":"Biundo R, Weis L, Antonini A. Cognitive decline in Parkinson\u2019s disease: the complex picture. npj Parkinson\u2019s Dis. 2016;2:16018.","journal-title":"npj Parkinson\u2019s Dis"},{"key":"514_CR64","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.neurobiolaging.2011.03.014","volume":"33","author":"R Fronczek","year":"2012","unstructured":"Fronczek R, van Geest S, Fr\u00f6lich M, Overeem S, Roelandse FWC, Lammers GJ, et al. Hypocretin (orexin) loss in Alzheimer\u2019s disease. Neurobiol Aging. 2012;33:1642\u201350.","journal-title":"Neurobiol Aging"},{"key":"514_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-12-394623-2.00015-9","volume":"89","author":"H Katsuki","year":"2012","unstructured":"Katsuki H, Michinaga S. Anti-Parkinson drugs and orexin neurons. Vitam Horm. 2012;89:279\u201390.","journal-title":"Vitam Horm"},{"key":"514_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/B978-0-12-394623-2.00002-0","volume":"89","author":"T Tsunematsu","year":"2012","unstructured":"Tsunematsu T, Yamanaka A. The role of orexin\/hypocretin in the central nervous system and peripheral tissues. Vitam Horm. 2012;89:19\u201333.","journal-title":"Vitam Horm"},{"key":"514_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.peptides.2017.12.017","volume":"101","author":"S Farahimanesh","year":"2018","unstructured":"Farahimanesh S, Karimi S, Haghparast A. Role of orexin-1 receptors in the dorsal hippocampus (CA1 region) in expression and extinction of the morphine-induced conditioned place preference in the rats. Peptides. 2018;101:25\u201331.","journal-title":"Peptides."},{"key":"514_CR68","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s11055-013-9849-2","volume":"43","author":"IG Sil\u2019kis","year":"2013","unstructured":"Sil\u2019kis IG. Possible mechanisms for the effects of Orexin on hippocampal functioning and spatial learning (analytical review). Neurosci Behav Physiol. 2013;43:1049\u201357.","journal-title":"Neurosci Behav Physiol"},{"key":"514_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/7854_2016_57","volume":"33","author":"MH James","year":"2017","unstructured":"James MH, Mahler SV, Moorman DE, Aston-Jones G. A decade of Orexin\/Hypocretin and addiction: where are we now? Curr Top Behav Neurosci. 2017;33:247\u201381.","journal-title":"Curr Top Behav Neurosci"},{"key":"514_CR70","doi-asserted-by":"crossref","unstructured":"Calipari ES, Espa\u00f1a RA. Hypocretin\/orexin regulation of dopamine signaling: implications for reward and reinforcement mechanisms. Front Behav Neurosci. 2012;6 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3423791\/ .","DOI":"10.3389\/fnbeh.2012.00054"},{"key":"514_CR71","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/febs.14607","volume":"285","author":"DJ Surmeier","year":"2018","unstructured":"Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson\u2019s disease. FEBS J. 2018;285:3657\u201368.","journal-title":"FEBS J"},{"key":"514_CR72","doi-asserted-by":"crossref","unstructured":"Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, et al. Neuromelanin Imaging and Dopaminergic Loss in Parkinson\u2019s Disease. Front Aging Neurosci. 2016;8 [cited 2019 Jan 30]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4992725\/ .","DOI":"10.3389\/fnagi.2016.00196"},{"key":"514_CR73","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/me.2004-0389","volume":"20","author":"S Ammoun","year":"2006","unstructured":"Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, et al. OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. Mol Endocrinol. 2006;20:80\u201399.","journal-title":"Mol Endocrinol"},{"key":"514_CR74","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1677\/JOE-08-0536","volume":"202","author":"M Ramanjaneya","year":"2009","unstructured":"Ramanjaneya M, Conner AC, Chen J, Kumar P, Brown JEP, J\u00f6hren O, et al. Orexin-stimulated MAP kinase cascades are activated through multiple G-protein signalling pathways in human H295R adrenocortical cells: diverse roles for orexins a and B. J Endocrinol. 2009;202:249\u201361.","journal-title":"J Endocrinol"},{"key":"514_CR75","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bbadis.2010.11.003","volume":"1812","author":"S Zhan","year":"2011","unstructured":"Zhan S, Cai G-Q, Zheng A, Wang Y, Jia J, Fang H, et al. Tumor necrosis factor-alpha regulates the Hypocretin system via mRNA degradation and ubiquitination. Biochim Biophys Acta. 2011;1812:565\u201371.","journal-title":"Biochim Biophys Acta"},{"key":"514_CR76","doi-asserted-by":"crossref","unstructured":"Castanon N, Luheshi G, Laye S. Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front Neurosci. 2015;9 [cited 2019 Apr 9]. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2015.00229\/full .","DOI":"10.3389\/fnins.2015.00229"},{"key":"514_CR77","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12974-018-1059-y","volume":"15","author":"JC d\u2019Avila","year":"2018","unstructured":"d\u2019Avila JC, Siqueira LD, Mazeraud A, Azevedo EP, Foguel D, Castro-Faria-Neto HC, et al. Age-related cognitive impairment is associated with long-term neuroinflammation and oxidative stress in a mouse model of episodic systemic inflammation. J Neuroinflammation. 2018;15:28.","journal-title":"J Neuroinflammation"},{"key":"514_CR78","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1523\/JNEUROSCI.2394-15.2016","volume":"36","author":"DB McKim","year":"2016","unstructured":"McKim DB, Niraula A, Tarr AJ, Wohleb ES, Sheridan JF, Godbout JP. Neuroinflammatory dynamics underlie memory impairments after repeated social defeat. J Neurosci. 2016;36:2590\u2013604.","journal-title":"J Neurosci"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-019-0514-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13041-019-0514-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-019-0514-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:25:22Z","timestamp":1721953522000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-019-0514-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1186\/s13041-019-0514-8","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}